This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/520230-astrazeneca-blood-clotting-ema/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Top EMA official says EU regulator to confirm link between AstraZeneca's vaccine and deadly blood clots | Top EMA official says EU regulator to confirm link between AstraZeneca's vaccine and deadly blood clots |
| (5 months later) | |
| The head of vaccines at the European Medicines Agency (EMA) says the body may soon officially confirm a connection between Vaxzevria – AstraZeneca's vaccine against Covid-19 – and cases of deadly cerebral venous thrombosis. | The head of vaccines at the European Medicines Agency (EMA) says the body may soon officially confirm a connection between Vaxzevria – AstraZeneca's vaccine against Covid-19 – and cases of deadly cerebral venous thrombosis. |
| “In my opinion, we can say now, it is clear there is a link between the vaccine” and rare cases of potentially deadly blood clots affecting people's brains, Marco Cavaleri told Italian newspaper Il Messaggero. | “In my opinion, we can say now, it is clear there is a link between the vaccine” and rare cases of potentially deadly blood clots affecting people's brains, Marco Cavaleri told Italian newspaper Il Messaggero. |
| He said the agency's investigation has not established the exact mechanism causing the thrombosis. If the problem is with the vector – Vaxzevria uses a rhesus chimpanzee adenovirus to deliver proteins from the SARS-CoV-2 coronavirus to train the immune system to defeat it – medics may need to reevaluate other vaccines using the same technique, the newspaper wrote. | He said the agency's investigation has not established the exact mechanism causing the thrombosis. If the problem is with the vector – Vaxzevria uses a rhesus chimpanzee adenovirus to deliver proteins from the SARS-CoV-2 coronavirus to train the immune system to defeat it – medics may need to reevaluate other vaccines using the same technique, the newspaper wrote. |
| The EMA's vaccine safety assessment committee PRAC is holding a conference this week. Updated guidelines for the use of Vaxzevria, which acknowledge the link, may come from the committee within hours, the official suggested. | The EMA's vaccine safety assessment committee PRAC is holding a conference this week. Updated guidelines for the use of Vaxzevria, which acknowledge the link, may come from the committee within hours, the official suggested. |
| Some EU countries have restricted use of the vaccine to people over 60, since the blood clotting side effects were mostly reported among younger people. Britain, which is relying heavily on the Oxford-developed vaccine to immunize its population, is reportedly considering a similar restriction for under 30s. | Some EU countries have restricted use of the vaccine to people over 60, since the blood clotting side effects were mostly reported among younger people. Britain, which is relying heavily on the Oxford-developed vaccine to immunize its population, is reportedly considering a similar restriction for under 30s. |
| The producer of the vaccine assured last month that its product’s safety was backed by scientific research, and that its review of data for vaccinations in the EU found no evidence of increased risk of blood clots. | The producer of the vaccine assured last month that its product’s safety was backed by scientific research, and that its review of data for vaccinations in the EU found no evidence of increased risk of blood clots. |
| Overall, the drug regulators which authorized Vaxzevria for emergency use believe that the benefits it offers far outweigh the risks of side effects. The number of reported blood clotting cases that developed after a Vaxzevria jab is measured in the dozens per tens of millions of vaccinated people. | Overall, the drug regulators which authorized Vaxzevria for emergency use believe that the benefits it offers far outweigh the risks of side effects. The number of reported blood clotting cases that developed after a Vaxzevria jab is measured in the dozens per tens of millions of vaccinated people. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |